A Novel Technique for Uveitis - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Novel Technique for Uveitis

Dr. David Chin Yee describes the benefits of delivering XIPERE directly into the suprachoroidal space

  • By

  • David Steve Chin Yee

  • July 20, 2026

  • 7 min

Share

Objective:

To discuss the clinical experiences with XIPERE and microneedle technology for treating uveitis.

Approach:
  • Interview with Dr. Chin Yee: Dr. Chin Yee shares insights on the use of XIPERE and microneedle technology for delivering treatment directly into the suprachoroidal space.
Key Findings:
  • XIPERE is an FDA-approved corticosteroid that can be delivered directly into the suprachoroidal space using microneedle technology.
  • This delivery method allows for better targeting of inflammation in the macula and potentially reduces side effects associated with traditional steroid treatments.
Interpretation:

The suprachoroidal space is an important target for treatment as it allows for direct access to the source of inflammation in uveitis.

Limitations:
  • There may be a learning curve associated with the new microneedle technology.
  • Funding for research in this area can be challenging.
Conclusion:

Collaboration between engineering and medicine is crucial for advancing ophthalmic innovations and improving patient outcomes.

Original Source(s)

A Novel Technique for Uveitis

  • by David Steve Chin Yee

  • July 20, 2026

Related Content

Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks

The Art of Ophthalmology 2026

Showcasing artwork and images from across the spectrum of ophthalmology

EULAR Updates Behçet’s Syndrome Recommendations

EULAR releases updated recommendations supporting earlier biologic use in patients with eye, vascular, and nervous system involvement